Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Abbey Color, Inc.
WARNING LETTER
•Abbey Color, Inc.•March 23, 2012

Abbey Color, Inc. – FDA Warning Letter, Mar 23, 2012

Record Details

An FDA inspection of Abbey Color, Inc.'s active pharmaceutical ingredient (API) manufacturing facility, conducted from March 13-23, 2012, identified significant deviations from current Good Manufacturing Practice (CGMP). These deviations cause the firm's APIs to be adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. The firm's response dated April 12, 2012, was deemed to lack sufficient corrective actions. Key violations included the failure to validate and monitor the water purification system to ensure appropriate quality, a repeat observation from a 2010 inspection, with continued out-of-specification (OOS) endotoxin and total organic carbon (TOC) results. The firm also failed to adequately investigate and document OOS test results, such as those for rinse water from equipment cleaning, indicating a lack of executive management oversight in identifying and remediating manufacturing control problems. Additionally, Abbey Color failed to establish an adequate stability program to monitor API characteristics and confirm storage conditions or retest/expiry dates, another repeat observation, with limited stability data and inadequate testing procedures. The FDA requires prompt corrective actions, including comprehensive gap analyses for the water system and OOS investigations, and a detailed stability program. The firm must respond within fifteen working days, outlining specific steps, timelines, and supporting documentation. Failure to comply may lead to legal action, including seizure and injunction, and impact federal contracts, export certificates, and drug application approvals. The FDA also requested contact with the Drug Shortages Program if production reductions are considered.

Company
Abbey Color, Inc.
Inspection date
March 23, 2012
Product type
Drugs
Office
Philadelphia District Office
Person
  • Kirk D. Sooter (District Director)
View Company Profile

ID · 50641cb8-670f-407f-b5d3-f6b124530134

Violation Codes2
21 U.S.C. 356C(a)(1)21 U.S.C. 351(a)(2)(B)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Abbey Color, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.